HK1218865A1 - 用於降低多发性硬化症中丘脑损伤的拉喹莫德 - Google Patents
用於降低多发性硬化症中丘脑损伤的拉喹莫德 Download PDFInfo
- Publication number
- HK1218865A1 HK1218865A1 HK16106893.7A HK16106893A HK1218865A1 HK 1218865 A1 HK1218865 A1 HK 1218865A1 HK 16106893 A HK16106893 A HK 16106893A HK 1218865 A1 HK1218865 A1 HK 1218865A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- laquinimod
- subject
- multiple sclerosis
- afflicted
- reducing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713256P | 2012-10-12 | 2012-10-12 | |
| US61/713,256 | 2012-10-12 | ||
| PCT/US2013/064061 WO2014058979A2 (en) | 2012-10-12 | 2013-10-09 | Laquinimod for reducing thalamic damage in multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1218865A1 true HK1218865A1 (zh) | 2017-03-17 |
Family
ID=50475887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16106893.7A HK1218865A1 (zh) | 2012-10-12 | 2013-10-09 | 用於降低多发性硬化症中丘脑损伤的拉喹莫德 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140107154A1 (enExample) |
| EP (1) | EP2961406A4 (enExample) |
| JP (1) | JP2015533163A (enExample) |
| KR (1) | KR20150080509A (enExample) |
| CN (1) | CN105263325A (enExample) |
| AR (1) | AR092993A1 (enExample) |
| AU (2) | AU2013329348A1 (enExample) |
| BR (1) | BR112015007782A2 (enExample) |
| CA (1) | CA2884272A1 (enExample) |
| CL (2) | CL2015000732A1 (enExample) |
| EA (1) | EA201590726A1 (enExample) |
| HK (1) | HK1218865A1 (enExample) |
| IL (1) | IL237745A0 (enExample) |
| MX (1) | MX2015004564A (enExample) |
| PE (1) | PE20151435A1 (enExample) |
| SG (1) | SG11201501874TA (enExample) |
| TW (1) | TW201420101A (enExample) |
| WO (1) | WO2014058979A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| AU2013221304B2 (en) | 2012-02-16 | 2017-12-21 | Teva Pharmaceutical Industries Ltd. | N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| CA2900503A1 (en) * | 2013-02-15 | 2014-08-21 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| AU2014364447A1 (en) * | 2013-12-20 | 2016-08-04 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to delay Huntington's disease progression |
| JP2017514824A (ja) | 2014-04-29 | 2017-06-08 | テバ ファーマシューティカル インダストリーズ リミティド | 能力障害度が高い再発寛解型多発性硬化症（ｒｒｍｓ）患者の処置のためのラキニモド |
| AU2016229982B2 (en) | 2015-03-09 | 2020-06-18 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| BR112019004791A2 (pt) * | 2016-09-13 | 2019-06-04 | Intekrin Therapeutics Inc | tratamento de esclerose múltipla com chs-131 |
| JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト |
| CN113397757A (zh) * | 2021-06-07 | 2021-09-17 | 温州医科大学 | 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2595159A1 (en) * | 2005-01-13 | 2006-07-20 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| WO2008009407A2 (en) * | 2006-07-17 | 2008-01-24 | Novartis Ag | Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators |
| TW201438738A (zh) * | 2008-09-16 | 2014-10-16 | 建南德克公司 | 治療進展型多發性硬化症之方法 |
| US20100322900A1 (en) * | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with laquinimod |
| DK2467372T3 (en) * | 2009-08-10 | 2016-08-22 | Teva Pharma | TREATMENT OF BDNF-RELATED DISEASES USING LAQUINIMOD |
| US20130035390A1 (en) * | 2010-01-13 | 2013-02-07 | Ramot At Tel-Aviv University Ltd. | Treatment of multiple sclerosis |
| MX2013006464A (es) * | 2010-12-07 | 2013-07-29 | Teva Pharma | Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple. |
| ES2602794T3 (es) * | 2011-03-31 | 2017-02-22 | Pfizer Inc | Piridinonas bicíclicas novedosas |
| US8889627B2 (en) * | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| TW201347762A (zh) * | 2012-05-02 | 2013-12-01 | Teva Pharma | 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途 |
-
2013
- 2013-10-09 HK HK16106893.7A patent/HK1218865A1/zh unknown
- 2013-10-09 AU AU2013329348A patent/AU2013329348A1/en not_active Abandoned
- 2013-10-09 JP JP2015536853A patent/JP2015533163A/ja active Pending
- 2013-10-09 BR BR112015007782A patent/BR112015007782A2/pt active Search and Examination
- 2013-10-09 EA EA201590726A patent/EA201590726A1/ru unknown
- 2013-10-09 WO PCT/US2013/064061 patent/WO2014058979A2/en not_active Ceased
- 2013-10-09 PE PE2015000472A patent/PE20151435A1/es not_active Application Discontinuation
- 2013-10-09 CN CN201380053184.1A patent/CN105263325A/zh active Pending
- 2013-10-09 KR KR1020157012465A patent/KR20150080509A/ko not_active Withdrawn
- 2013-10-09 CA CA2884272A patent/CA2884272A1/en not_active Abandoned
- 2013-10-09 SG SG11201501874TA patent/SG11201501874TA/en unknown
- 2013-10-09 US US14/049,411 patent/US20140107154A1/en not_active Abandoned
- 2013-10-09 EP EP13895446.6A patent/EP2961406A4/en not_active Withdrawn
- 2013-10-09 MX MX2015004564A patent/MX2015004564A/es unknown
- 2013-10-11 TW TW102136847A patent/TW201420101A/zh unknown
- 2013-10-11 AR ARP130103705A patent/AR092993A1/es unknown
-
2015
- 2015-03-15 IL IL237745A patent/IL237745A0/en unknown
- 2015-03-23 CL CL2015000732A patent/CL2015000732A1/es unknown
-
2016
- 2016-06-17 US US15/186,163 patent/US20160296511A1/en not_active Abandoned
- 2016-11-11 CL CL2016002873A patent/CL2016002873A1/es unknown
-
2017
- 2017-06-08 AU AU2017203896A patent/AU2017203896A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN105263325A (zh) | 2016-01-20 |
| CN105263325A8 (zh) | 2017-07-14 |
| CA2884272A1 (en) | 2014-04-17 |
| EP2961406A2 (en) | 2016-01-06 |
| IL237745A0 (en) | 2015-05-31 |
| EA201590726A1 (ru) | 2015-10-30 |
| US20140107154A1 (en) | 2014-04-17 |
| EP2961406A4 (en) | 2017-01-04 |
| WO2014058979A2 (en) | 2014-04-17 |
| AU2017203896A1 (en) | 2017-06-29 |
| KR20150080509A (ko) | 2015-07-09 |
| BR112015007782A2 (pt) | 2017-07-04 |
| US20160296511A1 (en) | 2016-10-13 |
| CL2016002873A1 (es) | 2017-04-17 |
| CL2015000732A1 (es) | 2015-08-07 |
| AR092993A1 (es) | 2015-05-13 |
| PE20151435A1 (es) | 2015-10-15 |
| SG11201501874TA (en) | 2015-05-28 |
| MX2015004564A (es) | 2015-07-21 |
| WO2014058979A8 (en) | 2015-04-16 |
| WO2014058979A3 (en) | 2015-08-20 |
| AU2013329348A1 (en) | 2015-05-28 |
| TW201420101A (zh) | 2014-06-01 |
| JP2015533163A (ja) | 2015-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX355065B (es) | Método y dispositivo para conmutación de cámaras. | |
| HK1218865A1 (zh) | 用於降低多发性硬化症中丘脑损伤的拉喹莫德 | |
| HK1199820A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fingolimod | |
| IN2014MN00333A (enExample) | ||
| HK1205941A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate | |
| HK1198278A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta | |
| WO2014031610A8 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| HK1211525A1 (en) | Laquinimod and pridopidine for treating neurodegenerative disorders | |
| WO2013169704A3 (en) | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | |
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| EP3143997A3 (en) | Methods of administering pirfenidone therapy | |
| WO2014080286A3 (en) | Methods and compositions for treating multiple sclerosis and related disorders | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| HK1218251A1 (zh) | 用拉喹莫德治疗多发性硬化症 | |
| WO2013087654A3 (en) | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation | |
| HK1209672A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fampridine | |
| PH12015500653A1 (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
| HK1225972A1 (zh) | 利用拉喹莫德来延缓亨廷顿氏病的进展 | |
| HK1223855A1 (zh) | 拉喹莫德和氟吡汀组合物用於治疗多发性硬化症 | |
| WO2013049280A3 (en) | Sphingosine analogs, compositions, and methods related thereto | |
| WO2015065628A3 (en) | Laquinimod combination therapy for treatment of multiple sclerosis | |
| HK1223854A1 (zh) | 通过阿仑单抗诱导随後通过拉喹莫德疗法来治疗多发性硬化症 | |
| PH12014500252A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate | |
| HK1230955A1 (en) | Cafestol for treating diabetes | |
| WO2014172453A3 (en) | Novel compositions useful in treating brain-related diseases or disorders and methods using same |